News

Under the collaboration, the companies will research and develop potential new medicines directed at about 10 GPCR targets. Heptares will apply its GPCR structure-guided platform to help offer

Anamorelin HCI is a novel, orally active selective ghrelin receptor agonist being developed to treat anorexia, cachexia, or unintended weight loss in NSCLC patients. Helsinn said ghrelin is

KU is the US specialty generic pharmaceuticals subsidiary of biopharmaceuticals firm UCB. The acquisition creates a key player in drug industry. The combined company generated pro-forma revenues of

Bristol-Myers Squibb planned to use the drug a single agent to treat previously untreated patients, specifically those with BRAF V600 mutation positive unresectable or metastatic melanoma. The company

The facility, which will be built next to the company’s two existing plants, will have 180,000 liters of capacity. The company said in a filing that it expects

biOasis’ Transcend Platform was originally based on the protein known as melanotransferrin (MTf or p97). Researchers at biOasis hypothesized that smaller sequences within the 80 kDa protein would

The world’s first Twin Robotic X-ray system, the Multitom Rax boasts a unique design that enables, for the first time, the acquisition of 3D natural weight-bearing images.¹ Siemens

Introduced at the 2015 Radiological Society of North America Annual Meeting (RSNA) in Chicago, IL , IntelliSpace Portal 8.0 helps address the changing demands in radiology that result

The partnership aims to offer a strategic research platform for Fox Chase Cancer Center – Temple Health and Accutest Research Laboratories to conduct clinical trials in the United